ID   CAH1_HUMAN              Reviewed;         261 AA.
AC   P00915;
DT   21-JUL-1986, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 2.
DT   12-APR-2017, entry version 184.
DE   RecName: Full=Carbonic anhydrase 1;
DE            EC=4.2.1.1;
DE   AltName: Full=Carbonate dehydratase I;
DE   AltName: Full=Carbonic anhydrase B;
DE            Short=CAB;
DE   AltName: Full=Carbonic anhydrase I;
DE            Short=CA-I;
GN   Name=CA1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=3104879; DOI=10.1093/nar/15.5.2386;
RA   Barlow J.H., Lowe N., Edwards Y.H., Butterworth P.H.W.;
RT   "Human carbonic anhydrase I cDNA.";
RL   Nucleic Acids Res. 15:2386-2386(1987).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=2121614; DOI=10.1016/0378-1119(90)90236-K;
RA   Lowe N., Brady H.J.M., Barlow J.H., Sowden J.C., Edwards M.,
RA   Butterworth P.H.W.;
RT   "Structure and methylation patterns of the gene encoding human
RT   carbonic anhydrase I.";
RL   Gene 93:277-283(1990).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Pancreas, and Spleen;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   PROTEIN SEQUENCE OF 2-261, CLEAVAGE OF INITIATOR METHIONINE, AND
RP   ACETYLATION AT ALA-2.
RX   PubMed=4217196; DOI=10.1016/S0300-9084(74)80093-3;
RA   Giraud N., Marriq C., Laurent-Tabusse G.;
RT   "Primary structure of human B erythrocyte carbonic anhydrase. 3.
RT   Sequence of CNBr fragment I and III (residues 149-260).";
RL   Biochimie 56:1031-1043(1974).
RN   [5]
RP   PROTEIN SEQUENCE OF 20-261.
RX   PubMed=4625868; DOI=10.1016/0006-291X(72)90400-7;
RA   Andersson B., Nyman P.O., Strid L.;
RT   "Amino acid sequence of human erythrocyte carbonic anhydrase B.";
RL   Biochem. Biophys. Res. Commun. 48:670-677(1972).
RN   [6]
RP   PROTEIN SEQUENCE OF 12-261.
RX   PubMed=4632246;
RA   Lin K.-T.D., Deutsch H.F.;
RT   "Human carbonic anhydrases. XI. The complete primary structure of
RT   carbonic anhydrase B.";
RL   J. Biol. Chem. 248:1885-1893(1973).
RN   [7]
RP   SEQUENCE REVISION.
RX   PubMed=4207120;
RA   Lin K.-T.D., Deutsch H.F.;
RT   "Human carbonic anhydrases. XII. The complete primary structure of the
RT   C isozyme.";
RL   J. Biol. Chem. 249:2329-2337(1974).
RN   [8]
RP   FUNCTION, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=10550681; DOI=10.1007/s007750050375;
RA   Briganti F., Mangani S., Scozzafava A., Vernaglione G., Supuran C.T.;
RT   "Carbonic anhydrase catalyzes cyanamide hydration to urea: is it
RT   mimicking the physiological reaction?";
RL   J. Biol. Inorg. Chem. 4:528-536(1999).
RN   [9]
RP   ENZYME REGULATION.
RX   PubMed=16807956; DOI=10.1002/chem.200600159;
RA   Temperini C., Scozzafava A., Vullo D., Supuran C.T.;
RT   "Carbonic anhydrase activators. Activation of isozymes I, II, IV, VA,
RT   VII, and XIV with l- and d-histidine and crystallographic analysis of
RT   their adducts with isoform II: engineering proton-transfer processes
RT   within the active site of an enzyme.";
RL   Chemistry 12:7057-7066(2006).
RN   [10]
RP   ENZYME REGULATION.
RX   PubMed=16686544; DOI=10.1021/jm0603320;
RA   Temperini C., Scozzafava A., Vullo D., Supuran C.T.;
RT   "Carbonic anhydrase activators. Activation of isoforms I, II, IV, VA,
RT   VII, and XIV with L- and D-phenylalanine and crystallographic analysis
RT   of their adducts with isozyme II: stereospecific recognition within
RT   the active site of an enzyme and its consequences for the drug
RT   design.";
RL   J. Med. Chem. 49:3019-3027(2006).
RN   [11]
RP   ENZYME REGULATION.
RX   PubMed=17127057; DOI=10.1016/j.bmcl.2006.11.027;
RA   Temperini C., Innocenti A., Scozzafava A., Mastrolorenzo A.,
RA   Supuran C.T.;
RT   "Carbonic anhydrase activators: L-Adrenaline plugs the active site
RT   entrance of isozyme II, activating better isoforms I, IV, VA, VII, and
RT   XIV.";
RL   Bioorg. Med. Chem. Lett. 17:628-635(2007).
RN   [12]
RP   ENZYME REGULATION.
RX   PubMed=19186056; DOI=10.1016/j.bmcl.2009.01.038;
RA   Crocetti L., Maresca A., Temperini C., Hall R.A., Scozzafava A.,
RA   Muehlschlegel F.A., Supuran C.T.;
RT   "A thiabendazole sulfonamide shows potent inhibitory activity against
RT   mammalian and nematode alpha-carbonic anhydrases.";
RL   Bioorg. Med. Chem. Lett. 19:1371-1375(2009).
RN   [13]
RP   ENZYME REGULATION.
RX   PubMed=19206230; DOI=10.1021/ja809683v;
RA   Maresca A., Temperini C., Vu H., Pham N.B., Poulsen S.-A.,
RA   Scozzafava A., Quinn R.J., Supuran C.T.;
RT   "Non-zinc mediated inhibition of carbonic anhydrases: coumarins are a
RT   new class of suicide inhibitors.";
RL   J. Am. Chem. Soc. 131:3057-3062(2009).
RN   [14]
RP   BIOPHYSICOCHEMICAL PROPERTIES, AND ENZYME REGULATION.
RX   PubMed=18618712; DOI=10.1002/prot.22144;
RA   Di Fiore A., Monti S.M., Hilvo M., Parkkila S., Romano V., Scaloni A.,
RA   Pedone C., Scozzafava A., Supuran C.T., De Simone G.;
RT   "Crystal structure of human carbonic anhydrase XIII and its complex
RT   with the inhibitor acetazolamide.";
RL   Proteins 74:164-175(2009).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [17]
RP   X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 2-260.
RX   PubMed=4622589; DOI=10.1016/0022-2836(72)90452-4;
RA   Kannan K.K., Fridborg K., Bergsten P.C., Liljas A., Loevgren S.,
RA   Petef M., Strandberg B., Waara I., Adler L., Falkbring S.O.,
RA   Goethe P.O., Nyman P.O.;
RT   "Structure of human carbonic anhydrase B. I. Crystallization and heavy
RT   atom modifications.";
RL   J. Mol. Biol. 63:601-604(1972).
RN   [18]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS).
RX   PubMed=804171; DOI=10.1073/pnas.72.1.51;
RA   Kannan K.K., Notstrand B., Fridborg K., Loevgren S., Ohlsson A.,
RA   Petef M.;
RT   "Crystal structure of human erythrocyte carbonic anhydrase B. Three-
RT   dimensional structure at a nominal 2.2-A resolution.";
RL   Proc. Natl. Acad. Sci. U.S.A. 72:51-55(1975).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 2-260 IN COMPLEX WITH ZINC
RP   ION.
RX   PubMed=6430186; DOI=10.1111/j.1749-6632.1984.tb12314.x;
RA   Kannan K.K., Ramanadham M., Jones T.A.;
RT   "Structure, refinement, and function of carbonic anhydrase isozymes:
RT   refinement of human carbonic anhydrase I.";
RL   Ann. N. Y. Acad. Sci. 429:49-60(1984).
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 2-260 IN COMPLEX WITH ZINC
RP   ION AND INHIBITORS.
RX   PubMed=15299369; DOI=10.1107/S0907444994001873;
RA   Kumar V., Kannan K.K., Sathyamurthi P.;
RT   "Differences in anionic inhibition of human carbonic anhydrase I
RT   revealed from the structures of iodide and gold cyanide inhibitor
RT   complexes.";
RL   Acta Crystallogr. D 50:731-738(1994).
RN   [21]
RP   X-RAY CRYSTALLOGRAPHY (1.60 ANGSTROMS) OF 2-260 IN COMPLEX WITH ZINC
RP   ION AND BICARBONATE.
RX   PubMed=8057362; DOI=10.1006/jmbi.1994.1491;
RA   Kumar V., Kannan K.K.;
RT   "Enzyme-substrate interactions. Structure of human carbonic anhydrase
RT   I complexed with bicarbonate.";
RL   J. Mol. Biol. 241:226-232(1994).
RN   [22]
RP   X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 2-260 IN COMPLEX WITH ZINC
RP   ION AND INHIBITORS.
RX   PubMed=7932756; DOI=10.1006/jmbi.1994.1655;
RA   Chakravarty S., Kannan K.K.;
RT   "Drug-protein interactions. Refined structures of three sulfonamide
RT   drug complexes of human carbonic anhydrase I enzyme.";
RL   J. Mol. Biol. 243:298-309(1994).
RN   [23]
RP   X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 2-260 IN COMPLEX WITH ZINC
RP   ION, AND VARIANT MICHIGAN-1 ARG-68.
RX   PubMed=12009884; DOI=10.1021/bi0120446;
RA   Ferraroni M., Tilli S., Briganti F., Chegwidden W.R., Supuran C.T.,
RA   Wiebauer K.E., Tashian R.E., Scozzafava A.;
RT   "Crystal structure of a zinc-activated variant of human carbonic
RT   anhydrase I, CA I Michigan 1: evidence for a second zinc binding site
RT   involving arginine coordination.";
RL   Biochemistry 41:6237-6244(2002).
RN   [24]
RP   X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 2-260 IN COMPLEX WITH ZINC
RP   ION AND ACTIVATORS, AND ACTIVATION BY IMIDAZOLE AND HISTIDINE.
RX   PubMed=16870440; DOI=10.1016/j.bmcl.2006.07.021;
RA   Temperini C., Scozzafava A., Supuran C.T.;
RT   "Carbonic anhydrase activators: the first X-ray crystallographic study
RT   of an adduct of isoform I.";
RL   Bioorg. Med. Chem. Lett. 16:5152-5156(2006).
RN   [25]
RP   X-RAY CRYSTALLOGRAPHY (1.55 ANGSTROMS) OF 2-260 IN COMPLEX WITH ZINC
RP   ION AND INHIBITORS, AND ENZYME REGULATION.
RX   PubMed=16506782; DOI=10.1021/ja057257n;
RA   Jude K.M., Banerjee A.L., Haldar M.K., Manokaran S., Roy B.,
RA   Mallik S., Srivastava D.K., Christianson D.W.;
RT   "Ultrahigh resolution crystal structures of human carbonic anhydrases
RT   I and II complexed with 'two-prong' inhibitors reveal the molecular
RT   basis of high affinity.";
RL   J. Am. Chem. Soc. 128:3011-3018(2006).
RN   [26]
RP   X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 6-260 IN COMPLEX WITH ZINC
RP   ION AND THE ANTIVIRAL FOSCARNET, AND ENZYME REGULATION.
RX   PubMed=17314045; DOI=10.1016/j.bmcl.2007.01.113;
RA   Temperini C., Innocenti A., Guerri A., Scozzafava A., Rusconi S.,
RA   Supuran C.T.;
RT   "Phosph(on)ate as a zinc-binding group in metalloenzyme inhibitors: X-
RT   ray crystal structure of the antiviral drug foscarnet complexed to
RT   human carbonic anhydrase I.";
RL   Bioorg. Med. Chem. Lett. 17:2210-2215(2007).
RN   [27]
RP   X-RAY CRYSTALLOGRAPHY (1.55 ANGSTROMS) OF 2-260 IN COMPLEX WITH ZINC
RP   ION AND INHIBITORS, AND ENZYME REGULATION.
RX   PubMed=17407288; DOI=10.1021/ja068359w;
RA   Srivastava D.K., Jude K.M., Banerjee A.L., Haldar M., Manokaran S.,
RA   Kooren J., Mallik S., Christianson D.W.;
RT   "Structural analysis of charge discrimination in the binding of
RT   inhibitors to human carbonic anhydrases I and II.";
RL   J. Am. Chem. Soc. 129:5528-5537(2007).
RN   [28]
RP   VARIANT GUAM ARG-254.
RX   PubMed=6781336;
RA   Omoto K., Ueda S., Goriki K., Takahashi N., Misawa S., Pagaran I.G.;
RT   "Population genetic studies of the Philippine Negritos. III.
RT   Identification of the carbonic anhydrase-1 variant with CA1 Guam.";
RL   Am. J. Hum. Genet. 33:105-111(1981).
RN   [29]
RP   VARIANT MICHIGAN-1 ARG-68.
RX   PubMed=7866410; DOI=10.1002/humu.1380040411;
RA   Chegwidden W.R., Wagner L.E., Venta P.J., Bergenhem N.C.H.,
RA   Yu Y.-S.L., Tashian R.E.;
RT   "Marked zinc activation of ester hydrolysis by a mutation, 67-His
RT   (CAT) to Arg (CGT), in the active site of human carbonic anhydrase
RT   I.";
RL   Hum. Mutat. 4:294-296(1994).
CC   -!- FUNCTION: Reversible hydration of carbon dioxide. Can hydrates
CC       cyanamide to urea. {ECO:0000269|PubMed:10550681}.
CC   -!- CATALYTIC ACTIVITY: H(2)CO(3) = CO(2) + H(2)O.
CC   -!- COFACTOR:
CC       Name=Zn(2+); Xref=ChEBI:CHEBI:29105;
CC         Evidence={ECO:0000269|PubMed:12009884,
CC         ECO:0000269|PubMed:15299369, ECO:0000269|PubMed:16506782,
CC         ECO:0000269|PubMed:16870440, ECO:0000269|PubMed:17314045,
CC         ECO:0000269|PubMed:17407288, ECO:0000269|PubMed:6430186,
CC         ECO:0000269|PubMed:7932756, ECO:0000269|PubMed:804171,
CC         ECO:0000269|PubMed:8057362};
CC   -!- ENZYME REGULATION: Activated by histamine, imidazole, L-
CC       adrenaline, L- and D-histidine, and L- and D-phenylalanine.
CC       Inhibited by coumarins, sulfonamide derivatives such as
CC       acetazolamide, benzenesulfonamide and derivatives (4-
CC       carboxyethylbenzene-sulfonamide, 4-carboxyethylbenzene-sulfonamide
CC       ethyl ester, 4-(acetyl-2-aminoethyl)benzene-sulfonamide, 4-
CC       aminoethylbenzene-sulfonamide), and 'prong inhibitors' BR15, BR17,
CC       BR22 and BR30. Activated by a short exposition to Foscarnet
CC       (phosphonoformate trisodium salt), but inhibited by a long one.
CC       Esterase activity weakly reduced by cyanamide.
CC       {ECO:0000269|PubMed:16506782, ECO:0000269|PubMed:16686544,
CC       ECO:0000269|PubMed:16807956, ECO:0000269|PubMed:17127057,
CC       ECO:0000269|PubMed:17314045, ECO:0000269|PubMed:17407288,
CC       ECO:0000269|PubMed:18618712, ECO:0000269|PubMed:19186056,
CC       ECO:0000269|PubMed:19206230}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=4.0 mM for CO(2) {ECO:0000269|PubMed:10550681,
CC         ECO:0000269|PubMed:18618712};
CC         KM=15 mM for 4-nitrophenyl acetate {ECO:0000269|PubMed:10550681,
CC         ECO:0000269|PubMed:18618712};
CC   -!- INTERACTION:
CC       Q12800:TFCP2; NbExp=6; IntAct=EBI-3912102, EBI-717422;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm.
CC   -!- SIMILARITY: Belongs to the alpha-carbonic anhydrase family.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X05014; CAA28663.1; -; mRNA.
DR   EMBL; M33987; AAA51910.1; -; mRNA.
DR   EMBL; BC027890; AAH27890.1; -; mRNA.
DR   CCDS; CCDS6237.1; -.
DR   PIR; JQ0786; CRHU1.
DR   RefSeq; NP_001122301.1; NM_001128829.3.
DR   RefSeq; NP_001122302.1; NM_001128830.3.
DR   RefSeq; NP_001122303.1; NM_001128831.3.
DR   RefSeq; NP_001158302.1; NM_001164830.1.
DR   RefSeq; NP_001729.1; NM_001738.4.
DR   UniGene; Hs.23118; -.
DR   PDB; 1AZM; X-ray; 2.00 A; A=2-261.
DR   PDB; 1BZM; X-ray; 2.00 A; A=2-261.
DR   PDB; 1CRM; X-ray; 2.00 A; A=2-261.
DR   PDB; 1CZM; X-ray; 2.00 A; A=2-261.
DR   PDB; 1HCB; X-ray; 1.60 A; A=2-261.
DR   PDB; 1HUG; X-ray; 2.00 A; A=2-261.
DR   PDB; 1HUH; X-ray; 2.20 A; A=2-261.
DR   PDB; 1J9W; X-ray; 2.60 A; A/B=2-261.
DR   PDB; 1JV0; X-ray; 2.00 A; A/B=2-261.
DR   PDB; 2CAB; X-ray; 2.00 A; A=2-261.
DR   PDB; 2FOY; X-ray; 1.55 A; A/B=2-261.
DR   PDB; 2FW4; X-ray; 2.00 A; A/B=2-261.
DR   PDB; 2IT4; X-ray; 2.00 A; A/B=6-261.
DR   PDB; 2NMX; X-ray; 1.55 A; A/B=2-261.
DR   PDB; 2NN1; X-ray; 1.65 A; A/B=2-261.
DR   PDB; 2NN7; X-ray; 1.85 A; A/B=2-261.
DR   PDB; 3LXE; X-ray; 1.90 A; A/B=2-261.
DR   PDB; 3W6H; X-ray; 2.96 A; A/B=2-261.
DR   PDB; 3W6I; X-ray; 2.69 A; A/E=2-261.
DR   PDB; 4WR7; X-ray; 1.50 A; A/B=3-261.
DR   PDB; 4WUP; X-ray; 1.75 A; A/B=3-261.
DR   PDB; 4WUQ; X-ray; 1.75 A; A/B=3-261.
DR   PDB; 5E2M; X-ray; 1.41 A; A/B=3-261.
DR   PDBsum; 1AZM; -.
DR   PDBsum; 1BZM; -.
DR   PDBsum; 1CRM; -.
DR   PDBsum; 1CZM; -.
DR   PDBsum; 1HCB; -.
DR   PDBsum; 1HUG; -.
DR   PDBsum; 1HUH; -.
DR   PDBsum; 1J9W; -.
DR   PDBsum; 1JV0; -.
DR   PDBsum; 2CAB; -.
DR   PDBsum; 2FOY; -.
DR   PDBsum; 2FW4; -.
DR   PDBsum; 2IT4; -.
DR   PDBsum; 2NMX; -.
DR   PDBsum; 2NN1; -.
DR   PDBsum; 2NN7; -.
DR   PDBsum; 3LXE; -.
DR   PDBsum; 3W6H; -.
DR   PDBsum; 3W6I; -.
DR   PDBsum; 4WR7; -.
DR   PDBsum; 4WUP; -.
DR   PDBsum; 4WUQ; -.
DR   PDBsum; 5E2M; -.
DR   ProteinModelPortal; P00915; -.
DR   SMR; P00915; -.
DR   BioGrid; 107214; 4.
DR   IntAct; P00915; 4.
DR   STRING; 9606.ENSP00000256119; -.
DR   BindingDB; P00915; -.
DR   ChEMBL; CHEMBL261; -.
DR   DrugBank; DB08156; 3-[4-(AMINOSULFONYL)PHENYL]PROPANOIC ACID.
DR   DrugBank; DB00819; Acetazolamide.
DR   DrugBank; DB00381; Amlodipine.
DR   DrugBank; DB00436; Bendroflumethiazide.
DR   DrugBank; DB00562; Benzthiazide.
DR   DrugBank; DB01194; Brinzolamide.
DR   DrugBank; DB00880; Chlorothiazide.
DR   DrugBank; DB00606; Cyclothiazide.
DR   DrugBank; DB01119; Diazoxide.
DR   DrugBank; DB01144; Diclofenamide.
DR   DrugBank; DB00869; Dorzolamide.
DR   DrugBank; DB08846; Ellagic Acid.
DR   DrugBank; DB01031; Ethinamate.
DR   DrugBank; DB00311; Ethoxzolamide.
DR   DrugBank; DB08157; ETHYL 3-[4-(AMINOSULFONYL)PHENYL]PROPANOATE.
DR   DrugBank; DB00999; Hydrochlorothiazide.
DR   DrugBank; DB00774; Hydroflumethiazide.
DR   DrugBank; DB00703; Methazolamide.
DR   DrugBank; DB00423; Methocarbamol.
DR   DrugBank; DB00232; Methyclothiazide.
DR   DrugBank; DB08155; N-{2-[4-(AMINOSULFONYL)PHENYL]ETHYL}ACETAMIDE.
DR   DrugBank; DB01325; Quinethazone.
DR   DrugBank; DB01021; Trichlormethiazide.
DR   DrugBank; DB00909; Zonisamide.
DR   GuidetoPHARMACOLOGY; 2597; -.
DR   iPTMnet; P00915; -.
DR   PhosphoSitePlus; P00915; -.
DR   BioMuta; CA1; -.
DR   DMDM; 115449; -.
DR   DOSAC-COBS-2DPAGE; P00915; -.
DR   REPRODUCTION-2DPAGE; IPI00215983; -.
DR   REPRODUCTION-2DPAGE; P00915; -.
DR   UCD-2DPAGE; P00915; -.
DR   PaxDb; P00915; -.
DR   PeptideAtlas; P00915; -.
DR   PRIDE; P00915; -.
DR   TopDownProteomics; P00915; -.
DR   DNASU; 759; -.
DR   Ensembl; ENST00000431316; ENSP00000392338; ENSG00000133742.
DR   Ensembl; ENST00000523022; ENSP00000429798; ENSG00000133742.
DR   Ensembl; ENST00000523953; ENSP00000430656; ENSG00000133742.
DR   Ensembl; ENST00000542576; ENSP00000443517; ENSG00000133742.
DR   GeneID; 759; -.
DR   KEGG; hsa:759; -.
DR   CTD; 759; -.
DR   DisGeNET; 759; -.
DR   GeneCards; CA1; -.
DR   HGNC; HGNC:1368; CA1.
DR   HPA; CAB025790; -.
DR   HPA; HPA006558; -.
DR   MIM; 114800; gene.
DR   neXtProt; NX_P00915; -.
DR   OpenTargets; ENSG00000133742; -.
DR   PharmGKB; PA25984; -.
DR   eggNOG; KOG0382; Eukaryota.
DR   eggNOG; COG3338; LUCA.
DR   GeneTree; ENSGT00760000118915; -.
DR   HOGENOM; HOG000112637; -.
DR   HOVERGEN; HBG002837; -.
DR   InParanoid; P00915; -.
DR   KO; K01672; -.
DR   OMA; VTWIICK; -.
DR   OrthoDB; EOG091G0XFM; -.
DR   PhylomeDB; P00915; -.
DR   TreeFam; TF316425; -.
DR   BRENDA; 4.2.1.1; 2681.
DR   Reactome; R-HSA-1237044; Erythrocytes take up carbon dioxide and release oxygen.
DR   Reactome; R-HSA-1247673; Erythrocytes take up oxygen and release carbon dioxide.
DR   Reactome; R-HSA-1475029; Reversible hydration of carbon dioxide.
DR   SABIO-RK; P00915; -.
DR   EvolutionaryTrace; P00915; -.
DR   GeneWiki; CA1_(gene); -.
DR   GenomeRNAi; 759; -.
DR   PRO; PR:P00915; -.
DR   Proteomes; UP000005640; Chromosome 8.
DR   Bgee; ENSG00000133742; -.
DR   CleanEx; HS_CA1; -.
DR   ExpressionAtlas; P00915; baseline and differential.
DR   Genevisible; P00915; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0004064; F:arylesterase activity; IMP:CACAO.
DR   GO; GO:0004089; F:carbonate dehydratase activity; IMP:CACAO.
DR   GO; GO:0016836; F:hydro-lyase activity; IDA:CACAO.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0015701; P:bicarbonate transport; TAS:Reactome.
DR   GO; GO:0006730; P:one-carbon metabolic process; IEA:InterPro.
DR   Gene3D; 3.10.200.10; -; 1.
DR   InterPro; IPR001148; Carbonic_anhydrase_a.
DR   InterPro; IPR023561; Carbonic_anhydrase_a-class.
DR   InterPro; IPR018338; Carbonic_anhydrase_a-class_CS.
DR   InterPro; IPR018442; Carbonic_anhydrase_CA1.
DR   PANTHER; PTHR18952; PTHR18952; 1.
DR   PANTHER; PTHR18952:SF132; PTHR18952:SF132; 1.
DR   Pfam; PF00194; Carb_anhydrase; 1.
DR   SMART; SM01057; Carb_anhydrase; 1.
DR   SUPFAM; SSF51069; SSF51069; 1.
DR   PROSITE; PS00162; ALPHA_CA_1; 1.
DR   PROSITE; PS51144; ALPHA_CA_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Complete proteome; Cytoplasm;
KW   Direct protein sequencing; Lyase; Metal-binding; Polymorphism;
KW   Reference proteome; Zinc.
FT   INIT_MET      1      1       Removed. {ECO:0000269|PubMed:4217196}.
FT   CHAIN         2    261       Carbonic anhydrase 1.
FT                                /FTId=PRO_0000077409.
FT   DOMAIN        4    261       Alpha-carbonic anhydrase.
FT                                {ECO:0000255|PROSITE-ProRule:PRU01134}.
FT   REGION      200    201       Substrate binding. {ECO:0000250}.
FT   ACT_SITE     65     65       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU01134}.
FT   ACT_SITE    129    129       {ECO:0000250}.
FT   METAL        65     65       Zinc 2; in variant Michigan-1.
FT                                {ECO:0000269|PubMed:12009884}.
FT   METAL        68     68       Zinc 2; in variant Michigan-1.
FT                                {ECO:0000269|PubMed:12009884}.
FT   METAL        95     95       Zinc 1; catalytic.
FT                                {ECO:0000269|PubMed:12009884,
FT                                ECO:0000269|PubMed:15299369,
FT                                ECO:0000269|PubMed:16506782,
FT                                ECO:0000269|PubMed:16870440,
FT                                ECO:0000269|PubMed:17314045,
FT                                ECO:0000269|PubMed:17407288,
FT                                ECO:0000269|PubMed:6430186,
FT                                ECO:0000269|PubMed:7932756,
FT                                ECO:0000269|PubMed:804171,
FT                                ECO:0000269|PubMed:8057362}.
FT   METAL        97     97       Zinc 1; catalytic.
FT                                {ECO:0000269|PubMed:12009884,
FT                                ECO:0000269|PubMed:15299369,
FT                                ECO:0000269|PubMed:16506782,
FT                                ECO:0000269|PubMed:16870440,
FT                                ECO:0000269|PubMed:17314045,
FT                                ECO:0000269|PubMed:17407288,
FT                                ECO:0000269|PubMed:6430186,
FT                                ECO:0000269|PubMed:7932756,
FT                                ECO:0000269|PubMed:804171,
FT                                ECO:0000269|PubMed:8057362}.
FT   METAL       120    120       Zinc 1; catalytic.
FT                                {ECO:0000269|PubMed:12009884,
FT                                ECO:0000269|PubMed:15299369,
FT                                ECO:0000269|PubMed:16506782,
FT                                ECO:0000269|PubMed:16870440,
FT                                ECO:0000269|PubMed:17314045,
FT                                ECO:0000269|PubMed:17407288,
FT                                ECO:0000269|PubMed:6430186,
FT                                ECO:0000269|PubMed:7932756,
FT                                ECO:0000269|PubMed:804171,
FT                                ECO:0000269|PubMed:8057362}.
FT   METAL       201    201       Zinc 2; in variant Michigan-1.
FT                                {ECO:0000269|PubMed:12009884}.
FT   BINDING     200    200       Substrate. {ECO:0000269|PubMed:8057362}.
FT   MOD_RES       2      2       N-acetylalanine.
FT                                {ECO:0000269|PubMed:4207120,
FT                                ECO:0000269|PubMed:4217196}.
FT   VARIANT      68     68       H -> R (in variant Michigan-1; confers
FT                                enhanced esterase activity and an
FT                                additional zinc binding site).
FT                                {ECO:0000269|PubMed:12009884,
FT                                ECO:0000269|PubMed:7866410}.
FT                                /FTId=VAR_001378.
FT   VARIANT     143    143       A -> V (in dbSNP:rs7821248).
FT                                /FTId=VAR_048679.
FT   VARIANT     254    254       G -> R (in Guam; dbSNP:rs121909577).
FT                                {ECO:0000269|PubMed:6781336}.
FT                                /FTId=VAR_001379.
FT   CONFLICT     75     76       DN -> ND (in Ref. 4; AA sequence and 5;
FT                                AA sequence). {ECO:0000305}.
FT   TURN         10     12       {ECO:0000244|PDB:5E2M}.
FT   HELIX        14     19       {ECO:0000244|PDB:5E2M}.
FT   HELIX        22     25       {ECO:0000244|PDB:5E2M}.
FT   STRAND       26     28       {ECO:0000244|PDB:5E2M}.
FT   STRAND       32     34       {ECO:0000244|PDB:1J9W}.
FT   HELIX        36     38       {ECO:0000244|PDB:5E2M}.
FT   STRAND       48     51       {ECO:0000244|PDB:5E2M}.
FT   HELIX        54     56       {ECO:0000244|PDB:5E2M}.
FT   STRAND       57     62       {ECO:0000244|PDB:5E2M}.
FT   STRAND       67     71       {ECO:0000244|PDB:5E2M}.
FT   STRAND       74     82       {ECO:0000244|PDB:5E2M}.
FT   STRAND       89     98       {ECO:0000244|PDB:5E2M}.
FT   STRAND      100    104       {ECO:0000244|PDB:1HCB}.
FT   STRAND      107    110       {ECO:0000244|PDB:5E2M}.
FT   STRAND      116    125       {ECO:0000244|PDB:5E2M}.
FT   TURN        126    128       {ECO:0000244|PDB:5E2M}.
FT   HELIX       132    135       {ECO:0000244|PDB:5E2M}.
FT   STRAND      141    153       {ECO:0000244|PDB:5E2M}.
FT   HELIX       156    158       {ECO:0000244|PDB:5E2M}.
FT   HELIX       159    164       {ECO:0000244|PDB:5E2M}.
FT   HELIX       165    167       {ECO:0000244|PDB:5E2M}.
FT   STRAND      174    176       {ECO:0000244|PDB:5E2M}.
FT   HELIX       182    185       {ECO:0000244|PDB:5E2M}.
FT   STRAND      192    197       {ECO:0000244|PDB:5E2M}.
FT   STRAND      208    215       {ECO:0000244|PDB:5E2M}.
FT   STRAND      217    219       {ECO:0000244|PDB:5E2M}.
FT   HELIX       221    228       {ECO:0000244|PDB:5E2M}.
FT   STRAND      230    233       {ECO:0000244|PDB:5E2M}.
SQ   SEQUENCE   261 AA;  28870 MW;  4959E5FA25E374F8 CRC64;
     MASPDWGYDD KNGPEQWSKL YPIANGNNQS PVDIKTSETK HDTSLKPISV SYNPATAKEI
     INVGHSFHVN FEDNDNRSVL KGGPFSDSYR LFQFHFHWGS TNEHGSEHTV DGVKYSAELH
     VAHWNSAKYS SLAEAASKAD GLAVIGVLMK VGEANPKLQK VLDALQAIKT KGKRAPFTNF
     DPSTLLPSSL DFWTYPGSLT HPPLYESVTW IICKESISVS SEQLAQFRSL LSNVEGDNAV
     PMQHNNRPTQ PLKGRTVRAS F
//
